A3 Adenosine Receptor Ligand for Fat Loss
Solution Overview
Problem
Current treatments for obesity often require combining weight loss procedures with medication, and existing compounds may have limitations in effectively reducing body fat and adipocyte proliferation.
Innovation Solution
The use of A3 adenosine receptor (A3AR) ligands, specifically 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (Cl-IB-MECA, CF102), which acts as an A3AR agonist to inhibit adipocyte proliferation and reduce body fat mass.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing compounds are used for weight loss, then some fat reduction effect is achieved, but the effectiveness in reducing body fat and inhibiting adipocyte proliferation is insufficient
Solution Approach 1:
The patent applies parameter changes by selecting and optimizing specific chemical structures of adenosine receptor ligands (particularly A3AR agonists) to achieve enhanced fat loss effects. The compound CF102 represents an optimized parameter set that demonstrates superior effectiveness in reducing body fat mass and inhibiting adipocyte proliferation compared to existing compounds.
2Quantity of substance
If A3AR ligands are used to reduce body fat mass, then fat loss effect is achieved, but the mechanism of action requires high specificity to avoid off-target effects
Solution Approach 1:
The patent applies local quality by designing ligands with high specificity for the A3 adenosine receptor subtype. The compound CF102 exhibits selective binding to A3AR, ensuring that the fat loss effect is achieved through targeted activation of the specific receptor pathway responsible for adipocyte proliferation and fat metabolism, while minimizing off-target effects on other adenosine receptor subtypes.
Data Source
AI summary
Provided is an A3 adenosine receptor (A3AR) ligand for use in achieving at least one fat loss effect selected from: reducing weight of the subject; reducing body fat mass in the subject; treating obesity in the subject and inhibiting adipocytes proliferation in a subject. The disclosure also concerns pharmaceutical compositions, methods of treatment and kits comprising the A3AR ligand.



